The U.S. osteoarthritis therapeutics market size was estimated at USD 2.15 billion in 2024 and is projected to reach USD 4.50 billion by 2033, growing at a CAGR of 8.61% from 2025 to 2033. Growing geriatric population, rising prevalence of obesity and joint injuries, and increasing demand for minimally invasive and regenerative therapies are driving the osteoarthritis therapeutics industry.
The aging population is a major factor driving the growth of the market. According to the Centers for Disease Control and Prevention (CDC), in February 2024, the age-adjusted prevalence of arthritis among U.S. adults aged 18 and older was 18.9%, with the prevalence in adults aged 75 and older reaching 53.9%. As the U.S. population ages, particularly with the elderly demographic projected to represent nearly 20% of the population by 2030, the demand for osteoarthritis treatments tailored to the older age group is increasing. In September 2024, the CDC reported that 40.3% of U.S. adults were classified as obese between August 2021 and August 2023. Obesity is a significant risk factor for osteoarthritis, especially in weight-bearing joints, and its high prevalence is contributing to the rising number of osteoarthritis cases.
Additionally, the increase in joint injuries, particularly those related to sports and work-related accidents, is accelerating the onset of osteoarthritis. As more individuals engage in physical activities, the likelihood of joint damage and subsequent osteoarthritis increases. In February 2024, the International Labour Organization (ILO) estimated that approximately 395 million workers worldwide sustain non-fatal work injuries annually, many of which result in joint damage. This has increased awareness of the need for joint health management and has contributed to the rising demand for osteoarthritis therapeutics in the U.S.
Finally, the shift toward minimally invasive and regenerative therapies is playing a significant role in shaping the U.S. osteoarthritis therapeutics market. There is growing interest in non-surgical treatments, such as hyaluronic acid injections, platelet-rich plasma (PRP) therapy, and stem cell therapies, as they offer effective alternatives with shorter recovery times and fewer side effects compared to traditional surgical options. This shift in treatment preferences is expected to continue fueling market growth in the coming years.
The industry is driven by the aging population, rising obesity rates, increasing joint injuries, and a growing preference for minimally invasive and regenerative therapies. These factors are expected to support continued market growth, with advancements in treatment technologies playing a key role in meeting the demands of an aging population.
This product will be delivered within 2 business days.
The aging population is a major factor driving the growth of the market. According to the Centers for Disease Control and Prevention (CDC), in February 2024, the age-adjusted prevalence of arthritis among U.S. adults aged 18 and older was 18.9%, with the prevalence in adults aged 75 and older reaching 53.9%. As the U.S. population ages, particularly with the elderly demographic projected to represent nearly 20% of the population by 2030, the demand for osteoarthritis treatments tailored to the older age group is increasing. In September 2024, the CDC reported that 40.3% of U.S. adults were classified as obese between August 2021 and August 2023. Obesity is a significant risk factor for osteoarthritis, especially in weight-bearing joints, and its high prevalence is contributing to the rising number of osteoarthritis cases.
Additionally, the increase in joint injuries, particularly those related to sports and work-related accidents, is accelerating the onset of osteoarthritis. As more individuals engage in physical activities, the likelihood of joint damage and subsequent osteoarthritis increases. In February 2024, the International Labour Organization (ILO) estimated that approximately 395 million workers worldwide sustain non-fatal work injuries annually, many of which result in joint damage. This has increased awareness of the need for joint health management and has contributed to the rising demand for osteoarthritis therapeutics in the U.S.
Finally, the shift toward minimally invasive and regenerative therapies is playing a significant role in shaping the U.S. osteoarthritis therapeutics market. There is growing interest in non-surgical treatments, such as hyaluronic acid injections, platelet-rich plasma (PRP) therapy, and stem cell therapies, as they offer effective alternatives with shorter recovery times and fewer side effects compared to traditional surgical options. This shift in treatment preferences is expected to continue fueling market growth in the coming years.
The industry is driven by the aging population, rising obesity rates, increasing joint injuries, and a growing preference for minimally invasive and regenerative therapies. These factors are expected to support continued market growth, with advancements in treatment technologies playing a key role in meeting the demands of an aging population.
U.S. Osteoarthritis Therapeutics Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. osteoarthritis therapeutics market report based on product, application, and primary user:Product Outlook (Revenue, USD Million, 2021-2033)
- Viscosupplements
- Platelet-Rich Plasma (PRP) Therapy
- Bone Graft Substitutes
- BMAC (Bone Marrow Aspirate Concentrate) Therapy
- Adipose Tissue Therapy
- Autologous Chondrocyte Implantation (ACI), Including MACI
- Stem Cell (other)
- Other (Cartilage Resurfacing Products)
Application Outlook (Revenue, USD Million, 2021-2033)
- Knee Osteoarthritis
- Hip Osteoarthritis
- Shoulder Osteoarthritis
- Spine Osteoarthritis
- Ankle & Foot Osteoarthritis
- Other
Primary User Outlook (Revenue, USD Million, 2021-2033)
- Orthopedic Surgeons
- Rheumatologists
- Sports Medicine Specialists
- Regenerative Medicine Specialists
- Other
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Osteoarthritis Therapeutics Market Variables, Trends, & Scope
Chapter 4. U.S. Osteoarthritis Therapeutics Market: Product Business Analysis
Chapter 5. U.S. Osteoarthritis Therapeutics Market: Application Business Analysis
Chapter 6. U.S. Osteoarthritis Therapeutics Market: Primary User Business Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The key companies profiled in this U.S. Osteoarthritis Therapeutics market report include:- Stryker
- Zimmer Biomet Holdings, Inc.
- Medtronic
- Anika Therapeutics, Inc.
- Bioventus
- Vericel Corporation
- Smith & Nephew
- Fidia Farmaceutici S.p.A.
- SEIKAGAKU CORPORATION
- Sanofi
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 190 |
| Published | November 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 2.15 Billion |
| Forecasted Market Value ( USD | $ 4.5 Billion |
| Compound Annual Growth Rate | 8.6% |
| Regions Covered | United States |
| No. of Companies Mentioned | 11 |
